XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

6 Months Ended

Jun. 30, 2015

Condensed Consolidated Financial Statements Detail [Abstract]

Outstanding securities considered anti-dilutive

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Common stock options and RSUs		8,362		7,939		7,850		6,576
Warrants for common stock		19,087		1,910		19,087		1,910
Total		27,449		9,849		26,937		8,486

Reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock

The following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Numerator
Net loss
Basic	$	(23,759	)	$	(11,897	)	$	(45,477	)	$	(16,584	)
Adjustment for revaluation of contingent warrant liabilities		-			(7,616	)		-			(27,150	)
Diluted	$	(23,759	)	$	(19,513	)	$	(45,477	)	$	(43,734	)

Denominator
Weighted average shares outstanding used for basic net loss per share		117,540			106,927			116,870			106,545
Effect of dilutive warrants		-			7,199			-			8,503
Weighted average shares outstanding and dilutive securities used for diluted net loss per share		117,540			114,126			116,870			115,048

Accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

	June 30, 2015		December 31, 2014
Accrued payroll and other benefits	$	2,851	$	3,061
Accrued management incentive compensation		2,300		4,295
Accrued clinical trial costs		1,081		1,424
Other		1,209		1,112
Total	$	7,441	$	9,892